Classical Hodgkin lymphoma-type and monomorphic-type post-transplant lymphoproliferative disorder following liver transplantation: a case report

Hiroyuki Kumata 1*, Chikashi Nakanishi 1, Keigo Murakami 2, Shigehito Miyagi 1, Noriko Fukuhara 3, Joaquim Carreras 4, Naoya Nakamura 4, Ryo Ichinohasama 5, Michiaki Unno 1, Takashi Kamei 1 and Hironobu Sasano 2

Abstract
Background: Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication that can be difficult to treat; moreover, determination of the pathophysiological type is difficult. We report a rare case of a patient who developed two types of Epstein–Barr virus (EBV)-negative PTLD following living donor liver transplantation (LDLT).

Case presentation: A 64-year-old man underwent LDLT for acute fulminant hepatitis B. Sixty-five months later, he developed EBV-negative monomorphic B cell PTLD. Reduction of immunosuppressive therapy and chemotherapy with rituximab resulted in a partial response. He received radioimmunotherapy with yttrium-90-ibritumomab tiuxetan, which was effective for all lesions, except for the splenic hilar lesion, which enlarged and seemed to penetrate the stomach. Therefore, he underwent resection of the pancreatic tail with splenectomy and partial gastrectomy. The pathological diagnosis was EBV-negative classical Hodgkin lymphoma (cHL)-type PTLD.

Conclusions: This patient showed an unexpected course of PTLD, from both a clinical and pathological perspective. There are no prior reports of an adult case of EBV-negative cHL-type PTLD coexisting with EBV-negative monomorphic B cell PTLD. When a strange and refractory lesion persists despite effective therapy for PTLD, we must consider the possibility of another type of PTLD within the residual lesion.

Keywords: Post-transplant lymphoproliferative disorder, Classical Hodgkin lymphoma, Liver transplantation

Background
Post-transplant lymphoproliferative disorder (PTLD) and susceptibility to infection are important and severe complications that occur secondary to the clinical use of potent immunosuppressive agents. According to 2008 World Health Organization classification, PTLD is categorized as one of the four major histological forms: early lesion, polymorphic PTLD, monomorphic PTLD, and classical Hodgkin lymphoma-type PTLD (cHL). In the clinic settings, monomorphic PTLD is observed most frequently, whereas cHL-type PTLD is uncommon [1]. It is suggested that most PTLD cases have a strong relationship with Epstein–Barr virus (EBV) [2]. Here we report a rare case of EBV-negative cHL-type PTLD, coexisting with EBV-negative monomorphic B cell PTLD following living donor liver transplantation (LDLT).

Case presentation
A 64-year-old man underwent LDLT from his daughter in May 2009 for acute fulminant hepatitis B. Both the recipient and donor had prior infection with EBV. The initial immunosuppression consisted of methylprednisolone and tacrolimus, with induction therapy using basiliximab. The trough level of tacrolimus was adjusted within the range of 3–4 ng/ml. Thereafter, he received tacrolimus (3 mg/day) and mycophenolate mofetil (500 mg/day), which kept...
the graft function in good condition. He had no history of immunological rejection in post-operative course until 65 months following LDLT, when he noted fever, pain in the left epigastrium, and nausea. He underwent computed tomography (CT) as a follow-up just 1 year before the onset of this symptom, but no abnormal findings were found in particular. CT revealed systemic lymphadenopathy, mainly in the abdomen, mediastinum, and bilateral cervical lymph nodes. In the splenic hilum, there was a large lymphadenopathy that compressed the stomach (Fig. 1a).

Upper gastrointestinal endoscopy revealed that a part of the gastric wall was compressed by the large lymphadenopathy in the splenic hilum on CT. We performed a biopsy from the lesion of the stomach; however, the result was inflammatory mucosa only, and we could not find a definitive diagnosis. Fluorodeoxyglucose positron emission tomography (FDG-PET) also showed systemic uptake corresponding to the area of lymphadenopathy on CT (Fig. 1b). His EBV viral load in the blood was undetectable. Biopsy from the cervical lymph node showed diffuse distortion of architecture, with hyperplasia of large and pleomorphic atypical lymphoid cells (Fig. 2a).

Flow cytometry for abnormal B cell populations revealed the following phenotypes: CD20+, CD10+, CD3−, CD56−, CD4+, and CD30−. Antibodies used for immunohistochemistry showed CD20+, CD10+, CD3−, CD5−, CD45+, CD56−, CD79a+, bcl2−, and bcl6+ (weak) (Fig. 2b and Table 1). EBV-encoded ribonucleic acid in situ hybridization (EBER-ISH) was negative in the tumor cells (Fig. 3a). From these findings, he was diagnosed with EBV-negative monomorphic B-cell PTLD.

The clinical course with the progress of serum lactate dehydrogenase and soluble interleukin-2 receptor is shown in Fig. 4. His immunosuppressive therapy was reduced. His target trough level of tacrolimus was adjusted to ≤4 ng/ml at the onset of PTLD, which is the target trough level during the treatment of PTLD at our institution. Therefore, we elected to discontinue mycophenolate mofetil without changing the dose of tacrolimus. Moreover, he received prednisolone, but there was minimal response. Thereafter, he received rituximab therapy; unfortunately, this treatment was slightly effective and the splenic hilar lymph node remained unchanged in size. Subsequently, he received radioimmunotherapy with yttrium-90-ibritumomab tiuxetan (90Y-IT). The agent 90Y-IT contains the anti-CD20 monoclonal antibody ibritumomab covalently bonded to the chelating agent tiuxetan and radiolabeled with 90Y. Three months after the therapy, the systemic lymphadenopathy resolved almost completely, except for the splenic hilar lesion, which seemed to progress uncontrollably and penetrate the stomach (Fig. 5a, b).

The patient underwent resection of the pancreatic tail with splenectomy and partial gastrectomy (Fig. 6a–c). The splenic hilar lesion was exposed in the lumen of the stomach (Fig. 6a). It was enlarged and compressed its surroundings, penetrating the stomach (Fig. 6b, c). Morphologically, the specimen revealed few large dyskaryotic or multinucleated atypical lymphoid cells infiltrating the stomach wall, pancreas, and splenic artery and vein (Fig. 7a). The atypical lymphoid cells were suggested to be Hodgkin/Reed–Sternberg cells. Antibodies used for immunohistochemistry showed CD20−, CD3−, CD5−,
CD45+, CD56−, and CD79a+ and weak positivities for both CD30 and CD10 (Fig. 7b, c and Table 1). To reveal the relationship between the Hodgkin cells and the underlying monomorphic PTLD, we performed a double labeling detection method that combined FISH for breakpoint in BCL6 and immunohistochemical staining for CD30 on the Hodgkin cells, revealing rearrangement of BCL6 (Fig. 3b). EBER-ISH showed negativity in the tumor cells (Fig. 7d). His preoperative EBV viral load in the blood was also undetectable. Therefore, we diagnosed EBV-negative cHL-type PTLD.

Table 1 Immunohistochemical findings of each post-transplant lymphoproliferative disorder (PTLD)

| Antibody | 1st PTLD | 2nd PTLD |
|----------|----------|----------|
| CD3      | –        | –        |
| CD5      | –        | –        |
| CD10     | +        | +        |
| CD20     | +        | –        |
| CD30     | None     | +        |
| CD45     | +        | +        |
| CD56     | –        | –        |
| CD79a    | +        | +        |

1st PTLD Epstein–Barr virus (EBV)-negative monomorphic B-cell PTLD, 2nd PTLD EBV-negative classical Hodgkin lymphoma-type PTLD

Six months after the surgery, surveillance CT showed no recurrence of PTLD; the patient then resumed tacrolimus (3 mg/day).

Discussion

PTLD is regarded as distinct from hematological malignancies, which develop in non-transplant recipients [1]. PTLD has various origins; approximately 85% are B cell proliferations, 14% are T cell proliferations, and the remaining 1% are NK cell or plasmacyte proliferations [2].

The main risk factors for PTLD are age, EBV status, use of immunosuppressive agents, and the type of organ transplanted [2]. Most adults with PTLD are EBV-negative, whereas children with PTLD tend to be EBV-positive [1]. As a patient receives higher doses of immunosuppressive agents, the frequency of developing PTLD increases and the time to onset of PTLD shortens [4]. In our patient, therapeutic drug monitoring kept the levels of immunosuppressive agents in the appropriate range. There is a difference in the prevalence of PTLD according to the type of organ that is transplanted; the small intestine is the most affected (20%), followed by the lungs at 4–10%, heart at 1–6%, liver and kidneys at 1–3%, and other organs at an average of 10% [5]. At our institution, we encountered 95 pediatric cases (<18 years old) and 75 adult cases who underwent LDLT between July 1991 and December 2017. Among these, seven pediatric patients (7%) and two adult cases (3%) developed PTLD.
PTLD has a strong relationship with EBV, particularly in B cell proliferations [2]. Krasuska-Sławińska et al. reported that EBV has been identified in 90% of B cell-proliferating PTLDs [6]. In general, the time of development of EBV-negative PTLD occurs later than that of EBV-positive PTLD [7]. These features were seen in our case. EBV-negative PTLD remains lesser elucidated than EBV-positive PTLD. Among the nine PTLD cases that we have encountered at our institution, all seven pediatric PTLDs were EBV-positive, whereas both adult cases were EBV-negative. In general, the first choice of treatment for PTLD is the reduction of immunosuppression. Rituximab is theoretically effective for CD20-positive PTLD but is only effective in approximately half of these patients [8]. In our case, considering that this patient was older and that the type of PTLD would be enough response by steroids, we did not initially use rituximab. However, because it was not possible to attain the expected response, we used rituximab. Recently, 90Y-IT has been reported to be effective in PTLD patients who were resistant to rituximab [8] as well as in patients with CD20-positive cHL [9]. In our case, 90Y-IT seemed to be effective for monomorphic PTLD but ineffective for cHL-type PTLD because of the negativity to CD20. Surgical therapy can also be effective and provide the correct diagnosis for localized PTLD, like in our cases [10]. His target trough of tacrolimus has been adjusted at a low level of ≤ 4 ng/ml both before and during PTLD [11]. Moreover, because he did not show recurrence and rejection findings after surgery, there was no need to change the target trough, and thus, he was observed at the same dose of tacrolimus.
For data pertaining to adjuvant chemotherapy, we searched PubMed and found no studies that reported on using adjuvant chemotherapy for PTLD after curative surgery. Further cases and studies are needed to reveal the effectiveness of adjuvant chemotherapy for PTLD after surgery.

Our case exhibited various histopathological types of PTLD. It was difficult to determine whether the cHL-type PTLD developed after the remission of monomorphic B cell PTLD; the two types of PTLD might have coexisted from the beginning. There are reports of two pediatric liver

Fig. 5 Preoperative image findings. a Preoperative computerized tomography and b fluorodeoxyglucose positron emission tomography demonstrated almost complete resolution of the systemic lymphadenopathy, except for the splenic hilar lymph node

Fig. 6 Macroscopic findings of the excised specimen. a A mass was exposed in the lumen of the stomach (white arrow). b, c The splenic hilar lesion was enlarged to compress the surroundings, penetrating the stomach (black arrow)
transplant patients [12–14] and one adult patient [15] who developed cHL-type PTLD subsequent to another type of PTLD (Table 2); all cases developed EBV-positive cHL-type PTLD after EBV-positive polymorphic B-cell PTLD [12, 14, 15]. Our case was very interesting due to simultaneous presentation of EBV-negative cHL-type PTLD and EBV-negative monomorphic B-cell PTLD.

In our case, the monomorphic PTLD showed rearrangement of BCL6 by FISH (Fig. 3a), whereas the cHL-type PTLD showed rearrangement of BCL6 during the double labeling detection method that combined FISH and immunohistochemical staining (Fig. 3b). From these results, we concluded that these two PTLDs might have a common origin. Several reports have shown that cHL and FL are

**Table 2** Features of classical Hodgkin lymphoma (cHL)-type post-transplant lymphoproliferative disorder (PTLD) subsequent to another PTLD following liver transplantation

| Case no. | Age/sex | Interval from transplant | Diagnosis | EBV positivity | Symptoms except lymphoadenopathy | Treatment | Outcome | Reference |
|----------|---------|--------------------------|-----------|----------------|----------------------------------|-----------|---------|-----------|
| 1        | 64 years/M | 5 years and 5 months | monomorphic PTLD | − | Fever, abdominal pain | Reduction of immunosuppression, rituximab, 90Y-IT | CR | Current case |
|          |         | 1 year from the 1st PTLD | cHL PTLD | − | Fever | Surgery |         |
| 2        | 28 years/F | 2 years and 2 months | Polymorphic PTLD | + | Fever | Reduction of immunosuppression, acyclovir | CR | 15 |
|          |         | 2 years and 5 months | cHL PTLD | + | Fever, splenomegaly | Reduction of immunosuppression, acyclovir, MOPP, splenectomy | CR |         |
| 3        | 9 years/M | 8 years from transplant | Polymorphic PTLD | + | Enlarged tonsil, adenoid | Reduction of immunosuppression, acyclovir | CR | 12 |
|          |         | 6 years and 10 months | cHL PTLD | + | Mediastinal mass | COPP, ABV | CR |         |
| 4        | 6 years/M | 4 years and 2 months | Polymorphic PTLD | + | None | Reduction of immunosuppression, gancyclovir | CR | 14 |
|          |         | 1 year and 6 months | cHL PTLD | + | Fever | MOPP, ABVD, radiation | CR |         |

**PTLD** post-transplant lymphoproliferative disorder, cHL classical Hodgkin lymphoma, M male, F female, 90Y-IT yttrium-90-ibritumomab tiuxetan, MOPP mechlorethamine, vincristine, procarbazine, prednisone, COPP cyclophosphamide, vincristine, procarbazine, prednisone, ABV doxorubicin, bleomycin, vinblastine, ABVD doxorubicin, bleomycin, vinblastine, dactarabazine, CR complete remission

*The systemic lymphadenopathy resolved almost completely, except for the splenic hilar lesion composed of cHL-type PTLD.*
derived from a shared germinal center B cell clone [16]. Nakamura et al. reported that FL converted to cHL by proving a rearrangement of BCL2 [17]. A rearrangement of BCL6 is mainly observed in FL or diffuse large B cell lymphoma and is rarely observed in cHL. With regard to PTLD cases, Poirel et al. reported three cases of mono-morphic type and one case of cHL type with rearrangement of BCL6 [18]. Five percent of patients who developed EBV-related PTLD developed another EBV-related PTLD, but there are no reports that can prove a causal relationship between the two types of PTLD [19]. To the best of our knowledge, there has been no report of EBV-negative monomorphic B cell PTLD converting to EBV-negative cHL-type PTLD by a rearrangement of BCL6 in the same patient following SOT.

Conclusions
When a strange and refractory PTLD lesion persists despite effective therapy, practitioners should consider the possibility of another type of PTLD in the residual lesion.

Abbreviations
PTLD: Post-transplant lymphoproliferative disorder; cHL: Classical Hodgkin lymphoma; EBV: Epstein–Barr virus; LDLT: Living donor liver transplantation; CT: Computed tomography; FDG-PET: Fluorodeoxyglucose positron emission tomography; EBER-ISH: Epstein–Barr virus-encoded ribonucleic acid in situ hybridization; FL: Follicular lymphoma; FISH: Fluorescence in situ hybridization; 90Y-T: Yttrium-90-ibritumomab tiuxetan

Availability of data and materials
The datasets used during the current report are available from the corresponding author on reasonable request.

Authors’ contributions
CN and SM performed the surgery and managed the perioperative course. TK and MU supervised the patient surgical treatment. HK, RM, and HS are pathologists who participated in the diagnosis of PTLD, and RI are medical oncologists who participated in the diagnosis and medical treatments of the patients. NN and JC performed a double labeling detection method that combined FISH for breakpoint in BCL6 and immunohistochemical staining for CD30 on the Hodgkin cells. KH, HK, NF, RI, and NN participated in discussion. HK wrote the manuscript. CN and NF supervised the writing of the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
The present study was conducted in accordance with the ethical standards of our institution.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and the accompanying images. A copy of the consent document is available for review by the editor-in-chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. Department of Surgery, Graduate School of Medicine, Tohoku University, 1-1 Seiryou-machi, Aobaku, Sendai 980-8574, Japan. 2. Department of Pathology, Graduate School of Medicine, Tohoku University, 1-1 Seiryou-machi, Aobaku, Sendai, Miyagi 980-8574, Japan. 3. Department of Surgery, Graduate School of Medicine, Tohoku University, 1-1 Seiryou-machi, Aobaku, Sendai, Miyagi 980-8574, Japan. 4. Department of Pathology, School of Medicine, Tokai University, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. 5. Division of Hematopathology, Tohoku University Hospital, 1-1 Seiryou-machi, Aobaku, Sendai, Miyagi 980-8574, Japan.

Received: 15 April 2018 Accepted: 28 June 2018

Published online: 06 July 2018

References
1. Jacobson CA, LaCasce AS. Lymphoma: risk and response after solid organ transplantation. Oncology. 2010;24(9–10):96–44.
2. Noguchi Y, Nakamura H, Ikegawa M, Ishii Y, Naka S, et al. Epstein–Barr virus-positive diffuse large B cell lymphoma of the elderly expresses EBNA3A with conserved CDB T cell epitopes. Am J Blood Res. 2011;1:146–59.
3. Krasuska-Slawinska E, Minko-Chojnowska I, Pawlowska J, Dembowska- Bąginska B, Pronicki M, Olczak-Kowalczyk D. Post-transplant lymphoproliferative disorder (PTLD) manifesting in the oral cavity of a 13- year-old liver transplant recipient (LTx). Ann Transplant. 2015;20:476–82.
4. Basgoz N, Preiksaitis JK. Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am. 1995;9:890–1.
5. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Casillas BL, Irani AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–9.
6. Herreman A, Dericco D, Morscio J, Camps J, Bitoun E, Vehoegh G, et al. Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases. Leuk Lymphoma. 2013;54:2190–9.
7. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol. 2009;27:3354–62.
8. Rossignol J, Terriou L, Robu D, Willekens C, Hivet B, Pascal L, et al. Radioimmunotherapy (90) Y-ibritumomab tiuxetan) for posttransplant lymphoproliferative disorders after prior exposure to rituximab. Am J Transplant. 2015;15:1976–81.
9. Schnell R, Dietlein M, Schomacker K, Kobe C, Borchmann P, Schicha H, et al. Yttrium-90 ibritumomab tiuxetan induced complete remission in a patient with classical lymphocyte- rich Hodgkin’s lymphoma. Onkologie. 2008;31:49–51.
10. Buadi FK, Heyman MR, Gocke CD, Rapoport AP, Hakimian R, Bartlett ST, et al. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study. Am J Hematol. 2007;82:209–14.
11. Orii T, Chihiro N, Satomi S, Hoshino Y, Kimura H. Decreasing the Epstein-Barr virus load by adjusting the FK506 blood level. Transpl Int. 2002;15:529–34.
12. Gheorghe G, Albano EA, Porter CC, McGavran L, Wei Q, Meltesen L, et al. Posttransplant lymphoproliferative lymphoma preceded by polymorphic posttransplant lymphoproliferative disorder: report of a pediatric case and review of the literature. J Pediatr Hematol Oncol. 2007;29:112–6.
13. Bassi S, Zecca M, Calafiore L, Rubert L, Ficochri R, Pauli M, et al. Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient. Pediatr Transplant. 2013;17:168–73.
14. Bierman PJ, Vosse JM, Langnas AN, Rifkin RM, Hauke RJ, Smir BN, et al. Hodgkin’s disease following solid organ transplantation. Ann Oncol. 1996;7:265–70.
15. Nalesnik MA, Randhawa P, Demetris AJ, Locker J, Casavilla A, Fung JJ. Lymphoma resembling Hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipient. Cancer. 1993;72:2568–73.
16. Kupper P, Sousa AB, Baur AS, Strickler JG, Rajevsky K, Hansmann ML. Common germinal-center B-cell origin of the malignant cells in two composite lymphomas, involving classical Hodgkin’s disease and either follicular lymphoma or B-CLL. Mol Med. 2001;7:285–92.
17. Nakamura N, Oshikina K, Abe M, Osamura Y. Demonstration of chimeric DNA of bcl-2 and immunoglobulin heavy chain in follicular lymphoma and
subsequent Hodgkin lymphoma from the same patient. J Clin Exp Hematop. 2007;47:9–13.

18. Poirel HA, Bernheim A, Schneider A, Meddeb M, Choquet S, Vr L, et al. Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status. Transplantation. 2005;80:176–84.

19. Wu T-t, Swerdlow SH, Locker J, Bahler D, Randhawa P, Yunis EJ, et al. Recurrent Epstein-Barr virus-associated lesions in organ transplant recipients. Hum Pathol. 1996;27:157–64.